Abstract
Glaucoma is the second leading cause of blindness worldwide and is predicted to affect nearly 80 million people globally by the end of the decade [1]. Characterized by progressive optic nerve damage and visual field loss, the cornerstone of glaucoma treatment involves reduction of intraocular pressure (IOP) by means of topical therapy, lasers or surgery in a bid to slow or prevent further progression of optic nerve damage and visual loss [1].
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call